Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.69 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16713383 | 0.94 | PPARG (0.59) | PPARGAGTR1PPARA | |
| SCHEMBL16713352 | 0.90 | PPARG (0.76) | PPARGAGTR1PPARA | |
| SCHEMBL14977096 | 0.90 | PPARG (0.76) | PPARGAGTR1PPARA | |
| SCHEMBL30300757 | 0.86 | PPARG (0.81) | PPARGAGTR1PPARA | |
| SCHEMBL14121063 | 0.86 | PPARG (0.81) | PPARGAGTR1PPARA | |
| SCHEMBL16713329 | 0.86 | PPARG (0.49) | PPARGAGTR1 | |
| SCHEMBL16713328 | 0.85 | NR1H4 (0.51) | PPARG | |
| SCHEMBL16731516 | 0.85 | PPARG (0.86) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30300648 | 0.85 | PPARG (0.81) | PPARGAGTR1PPARA | |
| SCHEMBL16713333 | 0.85 | BRD4 (0.49) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309227-B2 | N-biphenylmethylbenzimidazole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150141464-A1 | N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141464-A1 | N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG | CDK5, PPARG, CDK5R1 | PPARG 2/4885AGTR1 2139/4885CYP1A2 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.